SecBot SecBot
PRESS-RELEASE ·Filed Nov 2, 2026

SNDX

Syndax Pharmaceuticals, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed14d 10h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor the next quarterly earnings release for any changes in financial strategy or capital allocation under the new CFO. The transition appears orderly and non-disruptive.

DirectionNeutral
Confidencehigh
Horizonimmediate

Drugs in focus

SNDX drug pipeline →

Niktimvo

▲ Bullish Named in this press release
Impact
Phase
Approved
Time to market
Already approved and commercially launched (FDA approved August 2024)
Next catalyst
None dated

What to watchNiktimvo's commercial trajectory is the primary value driver for SNDX on this drug. Watch Q2/Q3 2026 net revenue prints for signs of continued ramp ($151.6M FY2025 annualizing to ~$220M in Q1 2026). The Phase 2 IPF readout in Q4 2026 is an important optionality catalyst that could open a much larger market, but comes with clinical risk. The $250M convertible note issued June 2026 introduces modest dilution overhang (~8-10% of shares outstanding).

Price Chart

Loading chart...

Executive Summary

Syndax Pharmaceuticals announced the appointment of Aaron A. Ondrey as CFO, effective November 9, 2026, replacing Keith A. Goldan who is retiring. The filing is a routine executive transition with no financial results or guidance provided, and no material impact on operations is expected.

Key Facts

  • Aaron A. Ondrey appointed as CFO effective November 9, 2026
  • Current CFO Keith A. Goldan retiring, will remain through end of 2026 to support transition
  • Mr. Ondrey previously CFO at Beren Therapeutics, Rocket Pharmaceuticals, and Mirati Therapeutics
  • No financial results, guidance, or operational updates were provided in this press release

Financial Impact

No financial figures disclosed; routine executive change with no stated financial impact.

Risk Factors

  • No financial data or guidance provided; the filing is purely a personnel announcement
  • CFO transition could introduce temporary uncertainty, though the outgoing CFO is staying through year-end

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3393696

US Market Status

Market Closed · Opens in 7h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026